Modeling therapy resistance via theEGFRsignaling pathway
نویسندگان
چکیده
منابع مشابه
Modeling Cancer Progression via Pathway Dependencies
Cancer is a heterogeneous disease often requiring a complexity of alterations to drive a normal cell to a malignancy and ultimately to a metastatic state. Certain genetic perturbations have been implicated for initiation and progression. However, to a great extent, underlying mechanisms often remain elusive. These genetic perturbations are most likely reflected by the altered expression of sets...
متن کاملThe phosphoinositide 3-kinase pathway and therapy resistance in cancer
The phosphoinositide 3-kinase (PI3K)/Akt/mechanistic target of rapamycin (mTOR) signaling network is a master regulator of processes that contribute to tumorigenesis and tumor maintenance. The PI3K pathway also plays a critical role in driving resistance to diverse anti-cancer therapies. This review article focuses on mechanisms by which the PI3K pathway contributes to therapy resistance in can...
متن کاملRegulation of Apoptosis via the NFκB Pathway: Modeling and Analysis
Programmed cell death (or apoptosis) has an essential biological function, enabling successful embryonic development, as well as maintenance of a healthy living organism [6]. Apoptosis is a physiological process which enables an organism to remove unwanted or damaged cells. Malfunctioning apoptotic pathways can lead to many diseases, including cancer and inflammatory or immune system related pr...
متن کاملUnderstanding the mTOR signaling pathway via mathematical modeling
The mechanistic target of rapamycin (mTOR) is a central regulatory pathway that integrates a variety of environmental cues to control cellular growth and homeostasis by intricate molecular feedbacks. In spite of extensive knowledge about its components, the molecular understanding of how these function together in space and time remains poor and there is a need for Systems Biology approaches to...
متن کاملResistance to HER2-targeted therapy
Production and approval of trastuzumab (Herceptin®) for the treatment of metastatic breast cancer (MBC) was a millstone in antibody-based targeted therapy in the cancer treatment. However, despite the early success in the clinical trials, trastuzumab failed to appreciate the initial attraction due to development of resistance to the drug. The majority of patients who benefit from the drug...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: The FEBS Journal
سال: 2019
ISSN: 1742-464X,1742-4658
DOI: 10.1111/febs.14809